Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Lupin Ltd (Lupin) develops and manufactures generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It has expertise in the areas of cardiovascular, asthma, diabetic management, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-TB, and cephalosporins. The company undertakes extensive research and development activities of pharmaceuticals for the treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes, inflammation, and others. Lupin also develops value-added generic pharmaceuticals based on its platform technologies. The company along with its subsidiaries operates manufacturing facilities in India, the US, Mexico, and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.

Headquarters India

Address B/4 Laxmi Towers, , Bandra Kurla Complex, Bandra (E), Mumbai, 400051


Telephone 91 22 66402222

No of Employees 18,573

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange LUPIN (NSE)

Revenue (2022) $2.2B

EPS XXX

Market Cap* $3.6B

Net Profit Margin (2021) XXX 558.3%

   

* As of and is in US$

Explore premium data & analytics

780+

Marketed Drugs

Understand Lupin Ltd’s commercialized product portfolio to stay one step ahead of the market.

150+

Clinical Trials

Determine Lupin Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

60+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Lupin Ltd’s relevant decision makers and contact details.

40+

Catalyst Calendar

Proactively evaluate Lupin Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

40+

Pipeline Drugs

Identify which of Lupin Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

8

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

6

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Anti-Tuberculosis: Tablets and Capsules Rcinex
Diabetes Management: Tablets, Injections, Capsules, Insulin Cartridge and Devices Akurit
Cardiac Care: Tablets, Injections, Capsules and Injectables AKT
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Corporate Changes/Expansions In June, the company announced Lupin Diagnostics launched its first regional reference laboratory in Patna, Bihar, India.
2022 Regulatory Approval In June, the company received tentative approval from the U.S. Food and Drug Administration (FDA) to market ivacaftor tablets, a generic version of the cystic fibrosis (CF) therapy Kalydeco.
2022 Regulatory Approval In May, the company received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Iloperidone Tablets to market a generic equivalent of Fanapt Tablets.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Lupin Ltd Sun Pharmaceutical Industries Ltd Cipla Ltd Dr. Reddy's Laboratories Ltd Intas Pharmaceuticals Ltd
Headquarters India India India India India
City Mumbai Mumbai Mumbai Hyderabad Ahmedabad
State/Province - - Maharashtra - Gujarat
No. of Employees 18,573 37,000 21,565 22,739 -
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Vinita Gupta Director; Chief Executive Officer Executive Board - -
Ramesh Swaminathan Chief Financial Officer; Head of Corporate Affairs; Director Executive Board 2020 -
Alok Sonig Global Head - Generics R&D & Biosimilars; Chief Executive Officer - US Generics Senior Management 2018 -
Manju D. Gupta Chairman Non Executive Board 2017 -
Sunil Makharia President - Finance Senior Management - -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer